O Orexo AB
O
Fermé
18.08 0.11
Résumé
Variation du prix de l'action
24h
Min
18.08
Max
18.54
Revenu | -68M -116M |
|---|---|
Ventes | -115M 3.3M |
BPA | 20.884 |
Marge bénéficiaire | -3,503.03 |
Employés | 74 |
EBITDA | -262M -272M |
Prochains Résultats | 16 juil. 2026 |
|---|
Capitalisation Boursière | -334M 700M |
|---|---|
Ouverture précédente | 17.97 |
Clôture précédente | 18.08 |
Orexo AB Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Orexo AB prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
